HUMIRA Improves Remission In Crohn's Patients

An open-label extension study of the CHARM and GAIN studies, performedin Abbott labs, demonstrate that patients with moderate-to-severeCrohn's disease who are treated with HUMIRA (adalimumab) actually achieved long-term clinical remission and a fullclinical response respectively.

UCB To Appeal European Negative Opinion On CIMZIA R For The Treatment Of Patients With Crohn's Disease

UCB announced that it has been informed by the European Medicines Agency (EMEA) that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the market authorisation application (MAA) in the EU for CIMZIA(R) certolizumab pegol) in the treatment of patients with Crohn's disease.

CHMP Adopts Negative Opinion On Appeal On European Application For Natalizumab For The Treatment Of Crohn's Disease

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion on the marketing authorization for natalizumab as a treatment for Crohn's disease.

Callisto Announces Presentation On Guanilib At 2007 Crohn's And Colitis Foundation National Research And Clinical Conference

Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, announced that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give an oral presentation covering preclinical data on Guanilib at the Crohn's and Colitis Foundation National Research and Clinical Conference - 6th Annual Advances in the Inflammatory Bowel Diseases during Dec.

Differing Physician And Patient Perceptions Regarding Impact Of UC Revealed by Nationwide Survey

Nearly three out of four patients with ulcerative colitis (UC) consider feeling unwell to be a normal part of life, while gastroenterologists estimate this to be true for only 37 percent of their UC patients, according to results from a nationwide series of surveys presented at the 2007 Crohn's & Colitis Foundation's 6th Annual Advances in the Inflammatory Bowel Diseases conference.

Scientists Find How Bacteria In Cows' Milk May Cause Crohn's Disease

Scientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn's disease in humans. Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.

Bacteria In Cows' Milk May Cause Crohn's Disease

Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.

FDA Approves Tysabri To Treat Moderate-To-Severe Crohn's Disease

The U.S. Food and Drug Administration has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.

Intestinal Inflammation Decreased By Il-22 Gene

There are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Conflicting reports have indicated that the soluble factor IL-22 can have both IBD promoting and IBD controlling effects. But now, Atsushi Mizoguchi and colleagues at Massachusetts General Hospital, Boston, have established that IL-22 ameliorates disease in a mouse model of UC.

FDA Approves Tysabri reg; For The Treatment Of Moderate-To-Severe Crohn's Disease

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for TYSABRI (natalizumab).